Company intelligence / Profile preview

Frontline

Shanghai, Shanghai, China

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Frontline BioVentures was a leading China-based venture capital firm investing in early- and growth-stage life sciences, particularly biopharma, medtech, and diagnostics; it merged in 2017 with WuXi Healthcare Ventures to form 6 Dimensions Capital, now managing USD 800m+ assets and portfolios across China and the US.

Therapeutic areas: OncologyOtherEndocrinology
Modalities: Small moleculeMonoclonal antibodymRNA-based drugsBiologicVaccinesMedical DevicesDiagnostics
Industry: Investors

Partnerships

Sinopharm (strategic partnerships for co-investment and distribution)WuXi Healthcare Ventures (merger partner, now 6 Dimensions Capital)

Beyond the preview

Go deeper on Frontline.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frontline.

Explore the full profile